NEW YORK, Aug. 27, 2025 /PRNewswire/ -- The Global CAR-T Cell Therapy Market is poised for exponential growth, projected to reach USD 217.6 billion by 2035, expanding at a compound annual growth rate (CAGR) of 39.75% from 2025 to 2035, according to a new comprehensive report by Vantage Market Research. This surge is driven by advances in personalized medicine, the growing global cancer burden, and an expanding portfolio of regulatory-approved therapies.
CAR-T therapies have demonstrated remarkable effectiveness in hematologic cancers such as leukemia, lymphoma, and multiple myeloma. The market is now advancing toward treating solid tumors-marking a critical frontier in oncology innovation.
"While much of the industry's focus has historically been on CAR-T in blood cancers, our study expands the lens to solid tumors and tracks over 1,000 global clinical trials, providing critical intelligence for biopharma strategy teams navigating this rapidly evolving landscape," said Nneha Rathod Godbole, Founder and CEO at Vantage Market Research. "CAR-T therapy is revolutionizing oncology care by transitioning from a last-resort option to a mainstream precision therapy with broad potential."
Click Here To Access The Free Sample Report @ https://www.vantagemarketresearch.com/car-tcell-therapy-market-2336/request-sample
(The Free Sample of This Report Is Readily Available on Request).
Our Free Sample Reports Includes:
- In-depth Industry Analysis, Introduction, Overview, and COVID-19 Pandemic Outbreak.
- Impact Analysis 215+ Pages Research Report (Including latest research)
- Provide chapter-wise guidance on request 2024 Updated Regional Analysis with Graphical Representation of Trends, Size, & Share, Includes Updated List of figures and tables.
- Updated Report Includes Major Market Players with their Sales Volume, Business Strategy and Revenue Analysis by using Vantage Market Research methodology.
CAR T-Cell Therapy Market Drivers
Rising Prevalence of Cancer
- According to WHO, cancer cases worldwide are expected to cross 28 million annually by 2040, highlighting the urgent need for breakthrough treatments.
- Hematological cancers such as non-Hodgkin's lymphoma and acute lymphoblastic leukemia are showing strong response rates to CAR-T cell therapies, creating significant traction.
- Traditional treatments like chemotherapy and stem cell transplantation have limited success rates, which positions CAR-T therapy as a last-resort life-saving intervention.
Strong Pipeline and Regulatory Approvals
- To date, multiple CAR-T therapies (e.g., Kymriah, Yescarta, Breyanzi, Abecma, Carvykti) have gained FDA and EMA approvals, reinforcing clinical validation.
- Over 1,000 active clinical trials globally are currently investigating CAR-T therapy applications, not only in hematologic cancers but also in solid tumors like glioblastoma, ovarian cancer, and lung cancer.
- Regulatory agencies are providing accelerated approvals and priority review designations to promising therapies, expediting commercialization timelines.
Strategic Collaborations and Investments
- Pharmaceutical leaders such as Novartis, Bristol Myers Squibb, Gilead/Kite Pharma, and Johnson & Johnson are investing heavily in R&D and manufacturing scalability.
- Collaborations between biotech startups and academic research institutions are driving innovation in CAR design, including allogeneic (off-the-shelf) CAR-T products that address cost and accessibility challenges.
- Global funding is also rising: for example, in 2024 alone, over USD 4.5 billion in venture capital funding flowed into cell and gene therapy companies.
List Of Prominent Players in the CAR T-Cell Therapy Market:
- Celgene Corporation (U.S.)
- Cartesian Therapeutics Inc. (U.S.)
- Miltenyi Biotech (Germany)
- Autolus Therapeutics (UK)
- Caribou Biosciences Inc. (U.S.)
- Gilead Sciences Inc. (U.S.)
- Merck & Co. Inc. (U.S.)
- Intellia Therapeutics (U.S.)
- Juno Therapeutics Inc. (U.S.)
- Bristol-Myers Squibb (U.S.)
- Novartis AG (Switzerland)
- Bluebird Bio Inc. (U.S.)
- Sorrento Therapeutics Inc. (U.S.)
- Pfizer Inc. (U.S.)
- Cellectis (France)
- Celyad Oncology (Belgium)
To Know an Additional List of Key Players, Request Here to Download a Free Report PDF Brochure: https://www.vantagemarketresearch.com/car-tcell-therapy-market-2336/request-sample
Why This Report Matters:
This report delivers in-depth insights into market dynamics, emerging trends, and future opportunities in the CAR T-Cell Therapy Market. It provides data-driven analysis to help stakeholders identify growth avenues, evaluate competitive strategies, and make informed investment decisions in this evolving sector.
Buy this Premium Research Report with Discount | Immediate Delivery @ https://www.vantagemarketresearch.com/car-tcell-therapy-market-2336/checkout
Recent Developments
- April 2025: Johnson & Johnson announced that the European Commission expanded the indication for its Darzalex (daratumumab) subcutaneous formulation. It is now approved in combination with bortezomib, lenalidomide, and dexamethasone for treating newly diagnosed multiple myeloma (NDMM) patients, including those ineligibles for transplant. Previously, the therapy was indicated only for transplant-eligible patients (ASCT).
- March 2025: Bristol Myers Squibb revealed plans to acquire 2seventy Bio for approximately USD 286 million. The two companies had earlier collaborated on Abecma, a CAR-T therapy targeting multiple myeloma.
- November 2024: The U.S. Food and Drug Administration (FDA) approved obecabtagene autoleucel (Aucatzyl, Autolus Inc.), a CD19-directed autologous CAR-T therapy, for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
Browse market data Tables and Figures(172) spread through 150+ Pages and in-depth TOC on CAR T-Cell Therapy Market Forecast Report (2025-2035).
Scope of the Report:
Market Size in 2024: USD 5.5 Billion
Revenue Forecast by 2035: USD 217.6 Billion
CAGR: 39.75% from 2025 to 2035
Base Year: 2024
Forecast Year: 2025 to 2035
Customization Options: Customized purchase options are available to meet any research needs. Explore customized purchase options https://www.vantagemarketresearch.com/car-tcell-therapy-market-2336/request-customization
Market Restraints
High Treatment Costs
- CAR-T therapy currently costs between USD 350,000 and USD 500,000 per patient, excluding hospitalization and supportive care expenses.
- Such pricing restricts accessibility in low- and middle-income regions and places financial pressure even on developed healthcare systems.
- Efforts to reduce costs via automation, improved supply chain, and off-the-shelf allogeneic CAR-T products are underway but still in early stages.
Safety Risks and Side Effects
- Despite high efficacy, CAR-T therapy carries risks of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).
- Managing these side effects requires specialized healthcare infrastructure and intensive monitoring, limiting widespread hospital adoption.
- Continued R&D is focused on next-gen CAR designs with "safety switches" to minimize these risks.
Global CAR-T Cell Therapy Market Segmentation:
Product:
- Yescarta
- Kymriah
- Carvykti
- Abecma
- Tecartus
- Breyanzi
- Others
Target:
- CD19
- BCMA
- CD20
- CD19/CD22
- Others
Indication:
- Multiple myeloma
- Follicular lymphoma
- Mantle cell lymphoma
- Acute lymphoblastic leukemia
- Others
Demographic:
- Adults
- Pediatrics
End User:
- Hospitals
- Specialty centers
- Long-term care facilities
Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Nordic Countries
- Benelux Union
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- South-East Asia
- Rest of Asia Pacific
- Latin America
- Brazil
- Argentina
- Rest of Latin America
- Middle East & Africa (MEA)
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of MEA
Read Full Report with TOC @ https://www.vantagemarketresearch.com/industry-report/car-tcell-therapy-market-2336
Frequently Asked Questions?
- What are the upcoming trends of CAR T-Cell Therapy Market in the globe?
- Which is the largest regional market for CAR T-Cell Therapy?
- What is the leading application of CAR T-Cell Therapy Market?
- What is the estimated industry size of CAR T-Cell Therapy?
- Which are the top companies to hold the market share in CAR T-Cell Therapy?
Regional Overview
North America remains the largest and most mature CAR-T cell therapy market, led by the United States, which benefits from early FDA approvals, strong reimbursement frameworks, and over 500 ongoing clinical trials, while Canada is steadily advancing with supportive infrastructure. Europe is witnessing consistent adoption, with the UK, Germany, and France establishing CAR-T centers of excellence and integrating therapies into national healthcare systems, despite cost and access challenges.
Asia-Pacific is the fastest-growing region, driven by China's leadership in clinical trials and biotech innovation, Japan's accelerated regulatory pathways, and South Korea's investments in advanced manufacturing, all supported by a rising cancer burden and expanded healthcare access. In Latin America, Brazil leads with active participation in international trials and government-backed initiatives, while Mexico and Argentina are increasingly collaborating with global biopharma firms despite cost barriers.
Meanwhile, the Middle East is seeing strong momentum from GCC nations like the UAE and Saudi Arabia, which are investing in advanced healthcare and global partnerships, whereas Africa's uptake remains limited but is expected to grow gradually as modernization and financing improve.
Reason to Buy this CAR T-Cell Therapy Market Report
- It provides a comprehensive overview of the CAR T-Cell Therapy market, including its size, growth, and trends.
- It analyzes the CAR T-Cell Therapy market by type, application, end-user, and geography.
- It provides insights into the competitive landscape of the CAR T-Cell Therapy market.
- It identifies and analyzes the key trends in the CAR T-Cell Therapy market.
- It provides a forecast of the CAR T-Cell Therapy market from 2025 to 2035.
- It helps you to understand the market dynamics and to make informed decisions.
- It helps you to identify the opportunities and challenges in the CAR T-Cell Therapy market.
- It helps you to plan and execute your marketing strategies more effectively.
- It helps you to understand the competitive landscape and to identify your competitors' strengths and weaknesses.
- It helps you to develop effective marketing strategies that will help you to increase your market share.
- It helps you to understand the market dynamics and to make informed decisions about your product development and marketing strategies.
Browse More Reports:
- Personalized Medicine Market Size, Share & Trends Analysis Report by Product (Personalized Medicine Diagnostics, Personalized Medicine Therapeutics, Personalized Medical Care, Personalized Nutrition & Wellness) by Application (Oncology, Neurology, Cardiology, Antiviral, Psychiatry, Immunology, Others) by End Users (Hospitals And Clinical Care, Diagnostic Companies And Testing Facilities, Academic Research Institutes And Research Laboratories, Contract Research Organizations, Bio And Health Informatics Companies, Others) by Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) - Historic Data (2021 - 2024) & Forecast Period (2025 - 2035)
- Cancer Immunotherapy Market Size, Share & Trends Analysis Report by Product (Monoclonal Antibodies, Immunomodulators, Oncolytic Viral Therapies & Cancer Vaccines) by Application (Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Head & Neck Cancer, Ovarian Cancer, Pancreatic Cancer, Other Cancers) by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) by End Use (Hospitals & Clinics, Cancer Research Centers, Other End Uses) by Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) - Historic Data (2021 - 2024) & Forecast Period (2025 - 2035)
- Cell Therapy Market Size, Share & Trends Analysis Report by Use-Type (Clinical Use, Research Use) by Type (Autologous Therapies, Allogenic Therapies) by Region (North America, Latin America, Europe, Asia Pacific, Middle East & Africa) - Historic Data (2021 - 2024) & Forecast Period (2023 - 2033)
- Orthobiologics Market Size, Share & Trends Analysis Report by Product type (Demineralized Bone Matrix (DBM), Allograft, Bone Morphogenetics Protein (BMP), Viscosupplementation, Synthetic Bone Substitutes, Stem Cell Therapy) by Application (Spinal Fusion, Trauma Repair, Reconstructive Surgery) by End Use (Hospitals, Outpatient Facilities) by Region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa) - Historic Data (2021 - 2024) & Forecast Period (2025 - 2035)
- Deoxyribonucleic Acid (DNA) Vaccines Market by Types (Human DNA Vaccines, Animal DNA Vaccines), by Application (Human diseases, Veterinary Diseases , Allergies and Others), by Region (North America, Latin America, Europe, Asia Pacific) - Historic Data (2021 - 2024) & Forecast Period (2025 - 2035)
About Vantage Market Research
Vantage Market Research is a trusted partner to Fortune 500 companies and leading biopharma firms, delivering actionable market intelligence across healthcare, biotechnology, and advanced cell therapies. Our globally recognized insights empower stakeholders to make informed decisions and capitalize on emerging opportunities.
Follow Us on: LinkedIn | Twitter | Facebook | YouTube
Contact us
Eric Kunz
224 W 35th St Ste 500,
New York, NY 10001
United States Tel: +1 202 380 9727
Email: sales@vantagemarketresearch.com
Website: https://www.vantagemarketresearch.com
Latest Vantage Market Research : Press Releases | Blog | Latest Reports
Research Insight: https://www.vantagemarketresearch.com/industry-report/car-tcell-therapy-market-2336
Content Source: https://www.vantagemarketresearch.com/press-release/car-t-cell-therapy-market-72585
Logo: https://mma.prnewswire.com/media/2758208/Vantage_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/global-car-t-cell-therapy-market-to-hit-217-6bn-by-2035-at-39-75-cagr--vantage-market-research-302539764.html
